s0122145
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.600
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.500
- IL6_JAK_STAT3_SIGNALING+0.400
- APOPTOSIS+0.100
- COMPLEMENT+0.100
- HEME_METABOLISM+0.100
- IL2_STAT5_SIGNALING+0.100
- INFLAMMATORY_RESPONSE+0.100
- KRAS_SIGNALING_DN+0.100
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.500
- ANGIOGENESIS-0.400
- PROTEIN_SECRETION-0.400
- TGF_BETA_SIGNALING-0.400
- CHOLESTEROL_HOMEOSTASIS-0.300
- HEDGEHOG_SIGNALING-0.300
- MTORC1_SIGNALING-0.300
- MYC_TARGETS_V1-0.300
- MYC_TARGETS_V2-0.300
- NOTCH_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GM-A2DO-01A-11R-A18M-07 | — | D | 0.913 |
| 2 | TCGA-AO-A0JC-01A-11R-A056-07 | — | D | 0.893 |
| 3 | b03d2223-38c1-4bb3-be8b-27db05f87b66 | — | — | 0.876 |
| 4 | ERR2208913 | — | — | 0.869 |
| 5 | AUR-AF95-TTP1-A-1-0-R-A741-41 | — | D | 0.859 |
| 6 | s0095135 | — | — | 0.854 |
| 7 | TCGA-4Z-AA7Q-01A-11R-A39I-07 | — | — | 0.854 |
| 8 | ERR4976617 | — | D | 0.848 |
| 9 | SRR25043622 | — | — | 0.846 |
| 10 | TCGA-S3-AA17-01A-11R-A41B-07 | — | D | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.600 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| COMPLEMENT | 0.100 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.100 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.100 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.100 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.100 | Cobimetinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.100 | Inavolisib | — uncovered |